Stay updated on BMS-936558 vs Standard Chemo in Advanced Melanoma Clinical Trial

Sign up to get notified when there's something new on the BMS-936558 vs Standard Chemo in Advanced Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the BMS-936558 vs Standard Chemo in Advanced Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the response rate or overall survival comparison between patients taking BMS-936558 and those taking Dacarbazine or Carboplatin and Paclitaxel in advanced melanoma post Anti-CTLA-4 therapy.
    Difference
    0.1%
    Check dated 2024-06-06T14:31:43.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed information about eligibility criteria for clinical trial participants, including examples and a link for more information. Previously, this section only indicated that no information was provided.
    Difference
    12%
    Check dated 2024-05-22T21:02:08.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T22:36:28.000Z thumbnail image

Stay in the know with updates to BMS-936558 vs Standard Chemo in Advanced Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the BMS-936558 vs Standard Chemo in Advanced Melanoma Clinical Trial page.